$0.96
$5.51
bear $0.96
base $2.44
bull $5.51
margin of safety $1.25
market price* $13.49
What the business is now. Ascent Industries (formerly Synalloy) is today a small specialty chemicals maker with three plants, in Cleveland, Tennessee; Fountain Inn, South Carolina; and Danville, Virginia. It makes surfactants, defoamers, lubricating agents, flame retardants and specialty intermediates, and does contract (custom) manufacturing for other chemical companies, serving cleaning products, coatings and adhesives, oilfield chemicals, agriculture, water treatment, pulp and paper and other industrial users. For most of the last decade the company was mainly a stainless steel pipe and tube business. It sold its last metals operation, Bristol Metals, on March 12, 2025 to a subsidiary of Ta Chen International, after earlier exits from the other metals units. Only the chemicals business remains, so the history before 2024 describes a different company and we do not use it to measure today's earning power. Earnings. We measure owner earnings as operating cash flow, stripped of working-capital swings, less stock-based pay and the capital spending needed to keep the plants running. On that basis the chemicals-only company has not yet earned money: about -$6.8 million (-$0.68 a share) in 2024 and -$3.8 million (-$0.39 a share) in 2025. Sales were $80.8 million in 2024 and $74.9 million in 2025. Gross margin improved from about 13% to 23% over those two years, and the operating loss narrowed from $10.8 million to $7.0 million (2025 included a $1.6 million non-cash impairment). In the first half of 2026, sales rose to $45.1 million from $36.5 million, helped by an acquisition of about $13.5 million. Owner earnings were roughly -$1.7 million for the half. The second quarter was close to break-even at the operating line (-$0.3 million) and showed a small net profit, but that is one quarter. The company has almost no interest cost, so the cash produced before lenders is essentially the same as the figures above. Our starting level is the middle of 2024 and 2025: about -$0.51 a share, or roughly -$4.6 million a year. Two further facts matter. The top five customers were 51% of 2025 sales, up from 35% in 2024. And the 2025 annual report disclosed material weaknesses in internal control over financial reporting that are still being fixed during 2026. Balance sheet. At June 30, 2026 the company had $28.1 million of cash, no bank borrowings (its revolving credit line was drawn and fully repaid during the half) and about $1.0 million of finance leases, so roughly $27.1 million of net cash, or about $2.97 a share on 9.11 million diluted shares. It also had about $18.4 million tied up in receivables and inventory, net of payables and accruals. Net cash has been falling: buybacks of $9.1 million in 2025 and $6.9 million in the first half of 2026, the acquisition, and the operating losses all came out of it. Bear case (about $0.96 a share). The chemicals business keeps losing money at its 2024-2025 average, about $4.6 million a year. In 2027-2028 a destocking downturn like 2023 arrives; in 2023 the chemicals segment's volumes fell 17% and sales 22%, and its operating result swung by about $8 million. Here that means losses of about $8 million a year for two years. Losing one of the five large customers would do similar damage. After five years of losses, about $30 million in all, which uses up the cash with a little help from the credit line, the operation is sold or wound down and half of its working capital is recovered. The business is worth about -$18 million against roughly $28 million of cash and $1 million of leases, leaving about $8.7 million for shareholders. Base case (about $2.44 a share). Losses run at the first-half 2026 rate, about $3.1 million, for the next year. In 2025 the annual loss narrowed by about $3.0 million (from roughly $6.5 million to $3.6 million before the very small interest bill). The base case narrows it by only about $0.5 million in its first year. Losses then narrow to about $1.5 million a year, halfway toward the near-break-even second quarter of 2026, because the margin gains of 2025 have held. We do not credit a return to profit, because the business has not yet produced one as a stand-alone chemicals company. Nothing we can point to sustains the operation in this form beyond ten years, so the story ends there, with the business sold or closed and three-quarters of its working capital recovered. The operating business is worth about -$4.8 million, plus $28.1 million of cash, less $1.0 million of leases: about $22.3 million in all. In other words, the median outcome is worth somewhat less than the cash on hand, because the operations are still using cash. Bull case (about $5.51 a share). The second-quarter 2026 run rate holds and improves with a full year of the acquired business: sales near $100 million at about the 2025 gross margin of 23%. Owner earnings turn positive in 2027 (about $1.5 million) and reach about $3 million a year from 2028. The same plants show this is achievable: the chemicals segment earned $7.0 million of segment operating income on $107.5 million of sales in 2022. The plants trace back to a business founded in 1945, so we let the $3 million fade to zero over the second decade rather than end it abruptly. The business is worth about $23 million, plus net cash of about $27 million: about $50 million in all. Growth and accounting choices. We credit no growth from the company's new Chemicals-as-a-Service strategy, from its sales pipeline or from future acquisitions, because none of it is contracted or yet visible in results. The narrowing of losses in the base case rests on improvement already reported: gross margin rose from 13% to 23%, and the operating loss shrank in 2025 and again in the first half of 2026. The 2025 impairment and a $2.3 million non-cash gain on a lease change were both removed from the earnings measure. The acquired business's amortization is small. We could not identify the business acquired in 2026 from the filings available to us. Earlier valuations of this company were built on the combined metals-and-chemicals history and on a different method, so those figures are not comparable with these. What could make this wrong. On the upside, the second quarter of 2026 may be the start of sustained profitability rather than a single good quarter. On the downside, management may keep spending the cash cushion on acquisitions and buybacks while the core operation still loses money, and the high customer concentration means one lost account could undo a year of progress. Margin-of-safety price. We are not confident of the earnings level. The current business has a two-year record, both years were losses, and the one encouraging quarter is not yet corroborated. The worst plausible outcome is a 2023-style destocking combined with the loss of a top customer while cash is being spent on deals. The company carries no debt, so it would survive that, but the cash per share would shrink toward $1. If the improvement stalls and the cash keeps going to acquisitions, the shares are worth about $1. The company pays no dividend, so returns depend entirely on the business turning profitable or management returning the cash, and the price assumes a holding period of about three years. A price of $1.25 a share is well under the cash on the balance sheet. From that price, reaching the base outcome within three years implies about a 25% annual return. The bear case implies a decline of about a quarter of that price, and that is the case in which most of the cash is spent first. That is why the margin-of-safety price is $1.25.